| P2093 | author name string | Clark RE | |
| | Butt NM | |
| P2860 | cites work | Prevention of transfusion-transmitted cytomegalovirus infection | Q33650397 |
| | Use of laboratory assays to predict cytomegalovirus disease in renal transplant recipients. | Q33683157 |
| | Primer-mediated enzymatic amplification of cytomegalovirus (CMV) DNA. Application to the early diagnosis of CMV infection in marrow transplant recipients | Q34569848 |
| | Human cytomegalovirus (HCMV) late-mRNA detection in peripheral blood of AIDS patients: diagnostic value for HCMV disease compared with those of viral culture and HCMV DNA detection | Q37130831 |
| | Detection of cytomegalovirus (CMV) in granulocytes by polymerase chain reaction compared with the CMV antigen test | Q40186852 |
| | Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years | Q40855744 |
| | Latent and persistent infections of monocytes and macrophages | Q41454448 |
| | Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group | Q44393577 |
| | Cytomegalovirus DNA in the sera of patients with cytomegalovirus pneumonia | Q44894727 |
| | Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group | Q45095772 |
| | A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group | Q47573431 |
| | Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation | Q57181379 |
| | Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia | Q68248914 |
| | Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation | Q68262204 |
| | Risk factors for cytomegalovirus infection after human marrow transplantation | Q70128484 |
| | Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation | Q70135390 |
| | Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant | Q72940232 |
| | Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT | Q73586578 |
| | The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation | Q74484143 |
| | Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts | Q77170463 |
| | Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients | Q77363538 |
| | Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance | Q78094091 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 615-619 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV. | |
| P478 | volume | 27 | |